Privately-held Italian drugmaker Menarini and USA/China-based SciClone Pharmaceuticals (Nasdaq: SCLN) have entered into an exclusive sub-licensing agreement to develop and commercialize Orserdu (elacestrant) in the People’s Republic of China, in an effort to expand treatment options for appropriate metastatic breast cancer (mBC) patients.
Orserdu is a once-daily oral endocrine monotherapy indicated for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
The drug was approved by the US Food and Drug Administration in in January this year under its priority review and fast track designation. In September, Orserdu was also was approved by the European Commission.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze